awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33431474-C98E5318-B245-4118-989D-6388D42B560C
Q33431474-C98E5318-B245-4118-989D-6388D42B560C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33431474-C98E5318-B245-4118-989D-6388D42B560C
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
P2860
Q33431474-C98E5318-B245-4118-989D-6388D42B560C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33431474-C98E5318-B245-4118-989D-6388D42B560C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ad5bfb792133f51621be59eadd9a3ba03bc0909e
P2860
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.